1. Scrip
  2. >>Focus On Asia
  3. >>China

Chinese Firms At JPM Not About China, It’s Time To Go Global

From Specialized Biotech To Global Biopharma In Decade

 
• By Brian Yang

From BeiGene to Innovent to Wuxi Biologics, executives at Chinese pharma firms are now discussing collaborations to go beyond China to become biopharma operations with a truly global presence.

JPM Roundtable 1
CHINA PHARMA LOOKING TO GO GLOBAL, NOTE EXECS AT JPM • Source: Alamy

10 years ago, business talks involving Chinese pharma firms mostly focused on trying to get some attention from established biopharma giants and venture capital investors. The tone today is more on becoming global operations themselves and the speed of growth of the new crop of companies from the country has been nothing short of astonishing.

The 40th Annual J.P. Morgan Global Healthcare Conference has always been a prime venue for such emerging bioventures to showcase...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By Xu Hu

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges